Back to top
more

TG Therapeutics (TGTX)

(Real Time Quote from BATS)

$14.27 USD

14.27
218,793

+0.02 (0.14%)

Updated Apr 24, 2024 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (152 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TGTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

TG Therapeutics, Inc. [TGTX]

Reports for Purchase

Showing records 181 - 200 ( 275 total )

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 181

05/14/2015

Company Report

Pages: 4

Glance at ASCO Update as Phase III Moves Along; Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 182

05/06/2015

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 183

05/06/2015

Company Report

Pages: 11

1Q15 Update-Signs of GENUINE Progress in Clinical Development

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 184

05/05/2015

Company Report

Pages: 5

1Q15 Results; Expect Additional Stock Upside with 2015 Catalysts

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 185

04/24/2015

Industry Report

Pages: 12

2015 AACR Meeting Highlights-Cancer Gets a Dose of Brotherly Love

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 186

04/21/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 187

04/20/2015

Company Report

Pages: 11

IRAK4 Program Gaining Momentum; Could Also Expand to Immune Setting

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 188

04/02/2015

Industry Report

Pages: 11

Healthcare: Shaky Sector; Focus on Defined Catalysts for Remainder of 2015

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 189

03/16/2015

Industry Report

Pages: 6

Healthcare Recap: Opportunities and Catalyst Focus Name of Game Going Forward

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 190

03/13/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 191

03/13/2015

Company Report

Pages: 13

4Q14 Update-Pipeline of Enviable Assets Marches to Registrational Studies

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 50.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 192

03/13/2015

Company Report

Pages: 7

FY2014 Results; Data and Pivotal Studies in 2015; Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 193

03/09/2015

Daily Note

Pages: 3

Building a Pipeline of Enviable Assets-TG Licenses Checkpoint Inhibitors

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 194

03/05/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 195

03/04/2015

Company Report

Pages: 4

Checking-In the Checkpoint Inhibitors Playing Field

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 196

12/11/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 197

12/10/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 198

12/10/2014

Industry Report

Pages: 14

ASH Highlights from Days 3-4 - Seeking the Right Combinations and Doses

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 50.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 199

12/10/2014

Company Report

Pages: 9

Oh What an ASH; Now What? Target Upped to $33; Reiterate Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: TG Therapeutics, Inc.

Industry: Medical - Products

Record: 200

12/09/2014

Company Report

Pages: 8

KOL Event; Great Data with Major Emphasis on Safety; Reiterate Focus Pick

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party